BION-1301 Treatment Results in Rapid and Durable Reductions in IgA and Gd-IgA1 in Patients with IgA Nephropathy Following both IV and SC dosing, BION-1301 produced rapid and sustained reductions in IgA and Gd-IgA1, the pathogenic variant of IgA nephropathy BION-1301 Treatment Results in ...

Atrasentan Treatment Results in Clinically Meaningful Proteinuria Reductions in Patients with IgAN Treatment with atrasentan results in durable and clinically meaningful proteinuria reductions in patients with IgAN receiving optimized standard of care Atrasentan was well-tolerated with no ...

Updated interim data to be presented from the IgA nephropathy (IgAN) patient cohort of the atrasentan phase 2 AFFINITY basket trial Additional interim data to be presented from Cohorts 1 and 2 of the ongoing phase 1/2 study of BION-1301 in patients with IgAN Research presentations include the ...

Chinook Therapeutics (NASDAQ:KDNY Get Rating) had its target price hoisted by HC Wainwright from $28.00 to $32.00 in a research report report published on Monday morning, MarketBeat reports. They currently have a buy rating on the stock. KDNY has been the topic of a number of other reports. ...

SEATTLE, July 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the European Commission has granted orphan drug designation for ...